Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

morning brief

- PMLiVE

BMS and Clovis join forces in PARP combo race

Duo will combine Opdivo and Rubraca in phase II and III trials to treat a variety of tumours

GSK hands new chief digital officer a transformative remit

Karenann Terrell will join the pharma firm from Walmart

- PMLiVE

GSK’s pipeline cull claims sirukumab, and possibly rare disease unit

Makeover designed to deliver a leaner, fitter company in 2020

Bristol Myers Squibb logo

BMS wins first US immuno-oncology paediatric licence

FDA gives the green light to expanded use of its melanoma treatment Yervoy

- PMLiVE

Shake-up at GSK could claim antibiotics unit and UK facilities

The firm says its plans, which are expected to lead to 320 job cuts, are not related to Brexit

- PMLiVE

Spark closes on first US gene therapy approval

FDA starts review of Luxturna for patients with inherited retinal disease

- PMLiVE

Novo launches personalised diabetes management mobile app

Partners with Glooko on app that syncs blood glucose and activity data

Bristol-Myers Squibb (BMS) building

Opdivo tops Yervoy in adjuvant melanoma trial

BMS’ nivolumab reduced the recurrence rate of melanoma compared to Yervoy

GSK signs up to apply AI to drug discovery

Will work with Exscientia on 10 small molecule targets

- PMLiVE

GSK signs up to apply AI to drug discovery

Will work with Exscientia on 10 small molecule targets

- PMLiVE

GSK starts trial of Nucala to seek alternate indications

Asthma therapy drug to be used to target severe nasal polyposis

- PMLiVE

GSK makes case for revaccination with Shingrix

The pharma giant seeks regulatory approval to treat people aged 50 plus

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links